on B.R.A.I.N. Biotechnology Research And Information Network AG (isin : DE0005203947)
BRAIN Biotech AG Refocuses on Profitable Growth
BRAIN Biotech AG is sharpening its focus on profitable growth by launching a new segment, BRAINBiocatalysts, to drive expansion. This initiative combines the BioProducts and BioScience Zwingenberg segments. The company aims to achieve EUR 100 million revenue and a 15% adjusted EBITDA margin in the next five years. Strategic moves, including collaborations with Royalty Pharma and Akribion Therapeutics, have improved liquidity and earnings.
The company is confident in its enzyme business's future, supported by a strong science foundation. CEO Adriaan Moelker emphasizes opportunities from bundling production and research activities. The BRAINBioIncubator sector also offers substantial potential through project commercializations.
With a focus on sustainable, profitable growth, CFO Michael Schneiders notes that the new segment strengthens their valuation. BRAIN Biotech anticipates significant positive impacts on sales and EBITDA through these strategic initiatives.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all B.R.A.I.N. Biotechnology Research And Information Network AG news